Experience of using tacrolimus as a part of a complex therapy of atopic dermatitis
| Autor: | Y. V. Kascheeva, N. N. Filimonkova, M. S. Kolbina |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2017 |
| Předmět: |
Moderate to severe
Drug tacropic medicine.medical_specialty media_common.quotation_subject такропик Topical treatment 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine lcsh:Dermatology Medicine clinical studies tacrolimus media_common Topical drug atopic dermatitis business.industry Hydrophobic drug топическая терапия такролимус Atopic dermatitis lcsh:RL1-803 medicine.disease Dermatology Tacrolimus Calcineurin body regions клинические исследования topical treatment 030220 oncology & carcinogenesis topical calcineurin inhibitors топические ингибиторы кальциневрина атопический дерматит business |
| Zdroj: | Vestnik Dermatologii i Venerologii, Vol 0, Iss 3, Pp 117-122 (2017) |
| ISSN: | 2313-6294 0042-4609 |
| Popis: | This review presents the results of international and Russian clinical studies conducted to assess the efficacy and safety of topical calcineurin inhibitors (TCIs) for the treatment of atopic dermatitis. The main mechanisms of action of TCIs are described. The authors demonstrate the advantages of Tacrolimus belonging to the TCI group. Due to the hydrophilic drug form and pharmacoeconomic index promoting compliance with treatment, it is possible to consider the new drug Tacropic (0.1% and 0.03% Tacrolimus ointments) as the optimum topical drug for the treatment of moderate to severe and severe forms of atopic dermatitis in adults and children. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|